Showing results (61-70 of 97) with videos related to
Sort By:
Pageof 10
The Journal of Antimicrobial Chemotherapy|December 25, 2019
Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adultsScott L Letendre, Anthony Mills, Debbie Hagins, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|September 12, 2022
Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical TrialsMaggie Czarnogorski, Paul Benn, Cindy McCoig, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 30, 2014
Investigation of metabolism and disposition of GSK1322322, a peptidase deformylase inhibitor, in healthy humans using the entero-test for biliary samplingDonna Mamaril-Fishman, John Zhu, Min Lin, et al.The American Journal of Drug and Alcohol Abuse|September 22, 2023
Meta-analysis of primary care delivered buprenorphine treatment retention outcomesRobert L Cooper, Ryan D Edgerton, Julia Watson, et al.Antimicrobial Agents and Chemotherapy|May 6, 2024
Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEPKelong Han, Parul Patel, Scott McCallister, et al.HIV Clinical Trials|November 18, 2018
Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trialMiranda I Murray, Martin Markowitz, Ian Frank, et al.Therapeutic Advances in Infectious Disease|December 18, 2023
Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirineParul Patel, Paula Teichner, Emilie Elliot, et al.British Journal of Clinical Pharmacology|July 9, 2021
Multicompartmental pharmacokinetic evaluation of long-acting cabotegravir in healthy adults for HIV preexposure prophylaxisJafar Sadik Shaik, Ethel D Weld, Stacey Edick, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 16, 2026
Impact of HIV-1 RNA Assay Selection on Low-Level Viremia and Clinical Trial Endpoint InterpretationsAnna Maria Geretti, Kehui Wang, Bliss Leverette, et al.Endocrine-Related Cancer|January 23, 2019
Genomic profiling of NETs: a comprehensive analysis of the RADIANT trialsJames Yao, Abhishek Garg, David Chen, et al.Pageof 10